CN102596932A - 作为酪氨酸苏氨酸激酶抑制剂的取代氨基喹喔啉 - Google Patents
作为酪氨酸苏氨酸激酶抑制剂的取代氨基喹喔啉 Download PDFInfo
- Publication number
- CN102596932A CN102596932A CN2010800490392A CN201080049039A CN102596932A CN 102596932 A CN102596932 A CN 102596932A CN 2010800490392 A CN2010800490392 A CN 2010800490392A CN 201080049039 A CN201080049039 A CN 201080049039A CN 102596932 A CN102596932 A CN 102596932A
- Authority
- CN
- China
- Prior art keywords
- phenyl
- quinoxalin
- alkyl
- piperazine
- pyridin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 CC(Cc(cc(*)cc1)c1/*=C1)C(C)C1=O Chemical compound CC(Cc(cc(*)cc1)c1/*=C1)C(C)C1=O 0.000 description 1
- ZIUUDTYYEITUSJ-UHFFFAOYSA-N CNS(Nc(cc1)ccc1-c1cc2nc(N3CCOCC3)cnc2cc1)(=O)=O Chemical compound CNS(Nc(cc1)ccc1-c1cc2nc(N3CCOCC3)cnc2cc1)(=O)=O ZIUUDTYYEITUSJ-UHFFFAOYSA-N 0.000 description 1
- ARPOBOFFMOLBKB-UHFFFAOYSA-N Cc1cc(-c(cc2)cc3c2ncc(N2CCN(C)CC2)n3)cc(C)c1O Chemical compound Cc1cc(-c(cc2)cc3c2ncc(N2CCN(C)CC2)n3)cc(C)c1O ARPOBOFFMOLBKB-UHFFFAOYSA-N 0.000 description 1
- PZGRGIHLECCNLD-UHFFFAOYSA-N Nc(ccc(-c1cc2nc(N3CCOCC3)cnc2cc1)c1)c1N Chemical compound Nc(ccc(-c1cc2nc(N3CCOCC3)cnc2cc1)c1)c1N PZGRGIHLECCNLD-UHFFFAOYSA-N 0.000 description 1
- RELDELLUOBLSTB-UHFFFAOYSA-N O=C(Cc1ccccc1)Nc(cc1)ccc1-c(cc1)cc2c1ncc(N(CC1)CCN1c1nccnc1)n2 Chemical compound O=C(Cc1ccccc1)Nc(cc1)ccc1-c(cc1)cc2c1ncc(N(CC1)CCN1c1nccnc1)n2 RELDELLUOBLSTB-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09075415.1 | 2009-09-04 | ||
| EP09075415 | 2009-09-04 | ||
| PCT/EP2010/005183 WO2011026579A1 (en) | 2009-09-04 | 2010-08-24 | Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102596932A true CN102596932A (zh) | 2012-07-18 |
Family
ID=43037638
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010800490392A Pending CN102596932A (zh) | 2009-09-04 | 2010-08-24 | 作为酪氨酸苏氨酸激酶抑制剂的取代氨基喹喔啉 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US9340528B2 (enExample) |
| EP (1) | EP2473498A1 (enExample) |
| JP (1) | JP5728683B2 (enExample) |
| CN (1) | CN102596932A (enExample) |
| CA (1) | CA2772790C (enExample) |
| WO (1) | WO2011026579A1 (enExample) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107935944A (zh) * | 2017-10-31 | 2018-04-20 | 广西师范大学 | 具有抗肿瘤活性双芳基脲喹喔啉衍生物及其合成方法 |
| CN104140395B (zh) * | 2013-05-08 | 2018-07-24 | 中国医学科学院药物研究所 | 丁炔酰胺衍生物及其制法和药物组合物与用途 |
| CN110981819A (zh) * | 2019-12-24 | 2020-04-10 | 广西师范大学 | 一种喹喔啉类信号通路抑制剂及其制备方法和应用 |
| CN111557899A (zh) * | 2020-04-30 | 2020-08-21 | 北华大学 | 一种治疗角膜炎的药物及其制备方法 |
| CN111689951A (zh) * | 2020-06-11 | 2020-09-22 | 西北师范大学 | 一种1-苄基-3-烷基喹喔啉-2(1h)-酮的合成方法 |
| US12084458B2 (en) | 2021-02-19 | 2024-09-10 | Sudo Biosciences Limited | Substituted pyridines, pyridazines, and pyrimidines as TYK2 inhibitors |
| US12122785B2 (en) | 2021-02-19 | 2024-10-22 | Sudo Biosciences Limited | Substituted pyridines, pyridazines, pyrimidines, and 1,2,4-triazines as TYK2 inhibitors |
Families Citing this family (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2343297A1 (en) | 2009-11-30 | 2011-07-13 | Bayer Schering Pharma AG | Triazolopyridines |
| EP2343294A1 (en) | 2009-11-30 | 2011-07-13 | Bayer Schering Pharma AG | Substituted triazolopyridines |
| GB201007286D0 (en) | 2010-04-30 | 2010-06-16 | Astex Therapeutics Ltd | New compounds |
| ES2555261T3 (es) | 2010-06-01 | 2015-12-30 | Bayer Intellectual Property Gmbh | Imidazopirazinas sustituidas |
| UY33452A (es) | 2010-06-16 | 2012-01-31 | Bayer Schering Pharma Ag | Triazolopiridinas sustituidas |
| TWI541243B (zh) | 2010-09-10 | 2016-07-11 | 拜耳知識產權公司 | 經取代咪唑并嗒 |
| GB201020179D0 (en) | 2010-11-29 | 2011-01-12 | Astex Therapeutics Ltd | New compounds |
| JP2013545776A (ja) | 2010-12-17 | 2013-12-26 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 過剰増殖性障害の治療におけるｍｐｓ−１およびｔｋｋ阻害剤として使用するための６置換イミダゾピラジン |
| EP2651945A1 (en) | 2010-12-17 | 2013-10-23 | Bayer Intellectual Property GmbH | 6-substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders |
| US20130303532A1 (en) | 2010-12-17 | 2013-11-14 | Bayer Intellectual Property Gmbh | Imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment hyperproliferative disorders |
| CA2821817A1 (en) | 2010-12-17 | 2012-06-21 | Bayer Intellectual Property Gmbh | Substituted 6-imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders |
| ES2530802T3 (es) | 2010-12-17 | 2015-03-06 | Bayer Ip Gmbh | Imidazopirazinas 6-tiosustituidas para uso como inhibidores de MPS-1 y TKK en el tratamiento de trastornos hiperproliferativos |
| CN103370322B (zh) | 2010-12-17 | 2016-02-10 | 拜耳知识产权有限责任公司 | 在过度增殖性病症的治疗中用作mps-1和tkk抑制剂的2-取代的咪唑并吡嗪 |
| WO2012088266A2 (en) | 2010-12-22 | 2012-06-28 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 |
| ES2571741T3 (es) | 2011-03-31 | 2016-05-26 | Bayer Ip Gmbh | Bencimidazoles sustituidos como inhibidores de Mps-1 quinasa |
| EP2694500B1 (en) | 2011-04-06 | 2015-05-27 | Bayer Pharma Aktiengesellschaft | Substituted imidazopyridines and intermediates thereof |
| DK2699575T3 (da) | 2011-04-21 | 2015-06-22 | Bayer Ip Gmbh | Triazolopyridiner |
| WO2012160029A1 (en) | 2011-05-23 | 2012-11-29 | Bayer Intellectual Property Gmbh | Substituted triazolopyridines |
| CN102250022B (zh) * | 2011-05-26 | 2013-10-16 | 浙江大学 | 取代喹喔啉胺类化合物及其制备方法和用途 |
| GB201118675D0 (en) | 2011-10-28 | 2011-12-14 | Astex Therapeutics Ltd | New compounds |
| GB201118652D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| GB201118654D0 (en) * | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| GB201118656D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| UA112096C2 (uk) | 2011-12-12 | 2016-07-25 | Байєр Інтеллектуал Проперті Гмбх | Заміщені триазолопіридини та їх застосування як інгібіторів ttk |
| EP2825540B1 (en) | 2012-03-14 | 2016-09-14 | Bayer Intellectual Property GmbH | Substituted imidazopyridazines |
| GB201209613D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
| GB201209609D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
| ES2984771T3 (es) | 2012-06-13 | 2024-10-31 | Incyte Holdings Corp | Compuestos tricíclicos sustituidos como inhibidores de FGFR |
| BR112015000308A2 (pt) | 2012-07-10 | 2017-06-27 | Bayer Pharma AG | método para preparo de triazolopiridinas substituídas |
| WO2014020043A1 (en) | 2012-08-02 | 2014-02-06 | Bayer Pharma Aktiengesellschaft | Combinations for the treatment of cancer |
| WO2014020041A1 (en) | 2012-08-02 | 2014-02-06 | Bayer Pharma Aktiengesellschaft | Combinations for the treatment of cancer |
| WO2014026125A1 (en) | 2012-08-10 | 2014-02-13 | Incyte Corporation | Pyrazine derivatives as fgfr inhibitors |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| EA035095B1 (ru) | 2013-04-19 | 2020-04-27 | Инсайт Холдингс Корпорейшн | Бициклические гетероциклы в качестве ингибиторов fgfr |
| GB201307577D0 (en) | 2013-04-26 | 2013-06-12 | Astex Therapeutics Ltd | New compounds |
| US9670202B2 (en) * | 2013-06-07 | 2017-06-06 | Bayer Pharma Aktiengesellschaft | Substituted triazolopyridines |
| US9586958B2 (en) | 2013-06-11 | 2017-03-07 | Bayer Pharma Aktiengesellschaft | Prodrug derivatives of substituted triazolopyridines |
| JO3512B1 (ar) | 2014-03-26 | 2020-07-05 | Astex Therapeutics Ltd | مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز |
| ES3014202T3 (en) | 2014-03-26 | 2025-04-21 | Astex Therapeutics Ltd | Cmet-inhibitors for use in delaying the emergence in resistance to fgfr inhibitors |
| HUE053653T2 (hu) | 2014-03-26 | 2021-07-28 | Astex Therapeutics Ltd | FGFR inhibitor és IGF1R inhibitor kombinációi |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| JOP20200201A1 (ar) | 2015-02-10 | 2017-06-16 | Astex Therapeutics Ltd | تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| EA038045B1 (ru) | 2015-02-20 | 2021-06-28 | Инсайт Корпорейшн | Бициклические гетероциклы в качестве ингибиторов fgfr |
| US9580423B2 (en) | 2015-02-20 | 2017-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| US10478494B2 (en) | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
| DK3283642T3 (da) | 2015-04-17 | 2024-01-02 | Crossfire Oncology Holding B V | Prognostiske biomarkører til ttk-hæmmerbaseret kemoterapi |
| WO2017019828A1 (en) * | 2015-07-30 | 2017-02-02 | Bristol-Myers Squibb Company | Aryl substituted bicyclic heteroaryl compounds |
| RU2747644C2 (ru) | 2015-09-23 | 2021-05-11 | Янссен Фармацевтика Нв | Бигетероарил-замещенные 1,4-бензодиазепины и пути их применения для лечения рака |
| HRP20201157T1 (hr) | 2015-09-23 | 2020-11-13 | Janssen Pharmaceutica N.V. | Triciklički heterocikli za liječenje raka |
| WO2017056498A1 (ja) * | 2015-09-30 | 2017-04-06 | 国立大学法人東北大学 | 糖尿病性腎症の判定マーカー |
| TWI691486B (zh) * | 2016-01-29 | 2020-04-21 | 日商東麗股份有限公司 | 環狀胺衍生物及其醫藥用途 |
| US10774064B2 (en) | 2016-06-02 | 2020-09-15 | Cadent Therapeutics, Inc. | Potassium channel modulators |
| BR112019007271A2 (pt) * | 2016-10-10 | 2019-09-17 | Dev Ct Biotechnology | compostos de quinoxalina como inibidores do receptor da tirosina quinase do tipo iii |
| CN110072860B (zh) * | 2016-12-20 | 2022-09-02 | 百时美施贵宝公司 | 可用作免疫调节剂的化合物 |
| CU24560B1 (es) | 2017-01-23 | 2021-12-08 | Cadent Therapeutics Inc | N-(4,4-difluorociclohexil)-2-(3-metil-1h-pirazol-1-il)-6-morfolinopirimidin-4-amina útil como modulador de canales de potasio |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| RS66310B1 (sr) | 2018-05-04 | 2025-01-31 | Incyte Corp | Čvrsti oblici inhibitora fgfr i procesi za njegovu pripremu |
| US11174257B2 (en) | 2018-05-04 | 2021-11-16 | Incyte Corporation | Salts of an FGFR inhibitor |
| US20200115389A1 (en) | 2018-09-18 | 2020-04-16 | Nikang Therapeutics, Inc. | Fused tricyclic ring derivatives as src homology-2 phosphatase inhibitors |
| AU2019366312B2 (en) | 2018-10-22 | 2025-04-24 | Novartis Ag | Crystalline forms of potassium channel modulators |
| TW202043205A (zh) | 2018-12-31 | 2020-12-01 | 美商拜歐米富士恩有限公司 | Menin-mll相互作用之抑制劑 |
| MX2021007925A (es) | 2018-12-31 | 2021-10-26 | Biomea Fusion Llc | Inhibidores irreversibles de la interaccion menina-mll. |
| WO2020185532A1 (en) | 2019-03-08 | 2020-09-17 | Incyte Corporation | Methods of treating cancer with an fgfr inhibitor |
| WO2021007269A1 (en) | 2019-07-09 | 2021-01-14 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| WO2021067374A1 (en) | 2019-10-01 | 2021-04-08 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| PH12022550892A1 (en) | 2019-10-14 | 2023-05-03 | Incyte Corp | Bicyclic heterocycles as fgfr inhibitors |
| US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| EP4069696A1 (en) | 2019-12-04 | 2022-10-12 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| AU2020395185A1 (en) | 2019-12-04 | 2022-06-02 | Incyte Corporation | Derivatives of an FGFR inhibitor |
| US12012409B2 (en) | 2020-01-15 | 2024-06-18 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| JP2024513575A (ja) | 2021-04-12 | 2024-03-26 | インサイト・コーポレイション | Ｆｇｆｒ阻害剤及びネクチン－４標的化剤を含む併用療法 |
| WO2022261160A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| TW202313610A (zh) | 2021-06-09 | 2023-04-01 | 美商英塞特公司 | 作為ｆｇｆｒ抑制劑之三環雜環 |
| CA3228627A1 (en) | 2021-08-11 | 2023-02-16 | Thomas Butler | Covalent inhibitors of menin-mll interaction for diabetes mellitus |
| CN119816500A (zh) | 2021-08-20 | 2025-04-11 | 拜欧米富士恩公司 | 用于治疗癌症的不可逆menin-MLL抑制剂N-[4-[4-(4-吗啉基)-7H-吡咯并[2,3-d]嘧啶-6-基]苯基]-4-[[3(R)-[(1-氧代-2-丙烯-1-基)氨基]-1-哌啶基]甲基]-2-吡啶甲酰胺的结晶形式 |
| WO2024155719A1 (en) | 2023-01-18 | 2024-07-25 | Biomea Fusion, Inc. | Crystalline forms of n-[4-[4-(4-morpholinyl)-7h-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(r)-[(l-oxo-2-propen-l-yl)amino]-l-piperidinyl]methyl]-2- pyridinecarboxamide as a covalentinhibitor of menin-mll interaction |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004346016A (ja) * | 2003-05-22 | 2004-12-09 | Otsuka Chemical Co Ltd | トリフルオロメチルキノキサリン化合物、その製造方法、及び有害生物防除剤 |
| WO2008141065A1 (en) * | 2007-05-10 | 2008-11-20 | Smithkline Beecham Corporation | Quinoxaline derivatives as p13 kinase inhibitors |
| WO2009021083A1 (en) * | 2007-08-09 | 2009-02-12 | Smithkline Beecham Corporation | Quinoxaline derivatives as pi3 kinase inhibitors |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US5011472A (en) | 1988-09-06 | 1991-04-30 | Brown University Research Foundation | Implantable delivery system for biological factors |
| AUPN842196A0 (en) * | 1996-03-05 | 1996-03-28 | Fujisawa Pharmaceutical Co., Ltd. | New compound |
| EP1001945B1 (en) | 1997-05-28 | 2011-03-02 | Aventis Pharmaceuticals Inc. | QUINOLINE AND QUINOXALINE COMPOUNDS WHICH INHIBIT PLATELET-DERIVED GROWTH FACTOR AND/OR p56lck TYROSINE KINASES |
| AU2003290734A1 (en) | 2002-11-27 | 2004-06-23 | Eli Lilly And Company | Novel compounds as pharmaceutical agents |
| AU2007284562B2 (en) | 2006-08-16 | 2013-05-02 | Exelixis, Inc. | Using PI3K and MEK modulators in treatments of cancer |
| EP2227770A4 (en) * | 2007-11-30 | 2011-11-09 | Glaxosmithkline Llc | PROLYLHYDROXYLASEINHIBITOREN |
| CA2725014C (en) * | 2008-05-30 | 2014-06-17 | Amgen Inc. | Inhibitors of pi3 kinase |
| CN102573846B (zh) * | 2009-08-17 | 2015-10-07 | 因特利凯公司 | 杂环化合物及其用途 |
-
2010
- 2010-08-24 CA CA2772790A patent/CA2772790C/en not_active Expired - Fee Related
- 2010-08-24 CN CN2010800490392A patent/CN102596932A/zh active Pending
- 2010-08-24 US US13/393,583 patent/US9340528B2/en not_active Expired - Fee Related
- 2010-08-24 JP JP2012527219A patent/JP5728683B2/ja not_active Expired - Fee Related
- 2010-08-24 EP EP10747595A patent/EP2473498A1/en not_active Withdrawn
- 2010-08-24 WO PCT/EP2010/005183 patent/WO2011026579A1/en not_active Ceased
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004346016A (ja) * | 2003-05-22 | 2004-12-09 | Otsuka Chemical Co Ltd | トリフルオロメチルキノキサリン化合物、その製造方法、及び有害生物防除剤 |
| WO2008141065A1 (en) * | 2007-05-10 | 2008-11-20 | Smithkline Beecham Corporation | Quinoxaline derivatives as p13 kinase inhibitors |
| WO2009021083A1 (en) * | 2007-08-09 | 2009-02-12 | Smithkline Beecham Corporation | Quinoxaline derivatives as pi3 kinase inhibitors |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104140395B (zh) * | 2013-05-08 | 2018-07-24 | 中国医学科学院药物研究所 | 丁炔酰胺衍生物及其制法和药物组合物与用途 |
| CN107935944A (zh) * | 2017-10-31 | 2018-04-20 | 广西师范大学 | 具有抗肿瘤活性双芳基脲喹喔啉衍生物及其合成方法 |
| CN107935944B (zh) * | 2017-10-31 | 2021-12-21 | 广西师范大学 | 具有抗肿瘤活性双芳基脲喹喔啉衍生物及其合成方法 |
| CN110981819A (zh) * | 2019-12-24 | 2020-04-10 | 广西师范大学 | 一种喹喔啉类信号通路抑制剂及其制备方法和应用 |
| CN110981819B (zh) * | 2019-12-24 | 2022-07-01 | 广西师范大学 | 一种喹喔啉类信号通路抑制剂及其制备方法和应用 |
| CN111557899A (zh) * | 2020-04-30 | 2020-08-21 | 北华大学 | 一种治疗角膜炎的药物及其制备方法 |
| CN111557899B (zh) * | 2020-04-30 | 2023-02-21 | 北华大学 | 一种治疗角膜炎的药物及其制备方法 |
| CN111689951A (zh) * | 2020-06-11 | 2020-09-22 | 西北师范大学 | 一种1-苄基-3-烷基喹喔啉-2(1h)-酮的合成方法 |
| US12084458B2 (en) | 2021-02-19 | 2024-09-10 | Sudo Biosciences Limited | Substituted pyridines, pyridazines, and pyrimidines as TYK2 inhibitors |
| US12103937B2 (en) | 2021-02-19 | 2024-10-01 | Sudo Biosciences Limited | Substituted pyridines and pyridazines as TYK2 inhibitors |
| US12122785B2 (en) | 2021-02-19 | 2024-10-22 | Sudo Biosciences Limited | Substituted pyridines, pyridazines, pyrimidines, and 1,2,4-triazines as TYK2 inhibitors |
Also Published As
| Publication number | Publication date |
|---|---|
| US9340528B2 (en) | 2016-05-17 |
| JP5728683B2 (ja) | 2015-06-03 |
| CA2772790C (en) | 2017-06-27 |
| JP2013503824A (ja) | 2013-02-04 |
| WO2011026579A1 (en) | 2011-03-10 |
| EP2473498A1 (en) | 2012-07-11 |
| US20120263708A1 (en) | 2012-10-18 |
| CA2772790A1 (en) | 2011-03-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102413831B (zh) | 取代的咪唑并喹喔啉 | |
| JP5728683B2 (ja) | チロシンスレオニンキナーゼ阻害剤としての置換アミノキノキサリン | |
| CN102858768B (zh) | 取代三唑并吡啶 | |
| JP5824065B2 (ja) | 過剰増殖性障害の治療におけるｍｐｓ−１およびｔｋｋ阻害剤として使用するための６置換イミダゾピラジン | |
| CN102762557B (zh) | 三唑并吡啶 | |
| JP5822944B2 (ja) | 過剰増殖性障害の治療におけるｍｐｓ−１およびｔｋｋ阻害剤として使用するための２置換イミダゾピラジン | |
| CN102971321B (zh) | 咪唑并吡嗪 | |
| CN104797585B (zh) | 氨基咪唑并哒嗪 | |
| US9745304B2 (en) | Amidoimidazopyridazines as MKNK-1 kinase inhibitors | |
| CN103038235B (zh) | 取代的咪唑并吡嗪 | |
| JP5951750B2 (ja) | 置換イミダゾピリジン類およびその中間体 | |
| CN103429592A (zh) | 作为mps-1和tkk抑制剂用于治疗过度增殖性病症的6-取代的咪唑并吡嗪 | |
| CN103582632B (zh) | 取代的苯并咪唑 | |
| CN103764656A (zh) | 杂环基氨基咪唑并哒嗪 | |
| CN103415518A (zh) | 在过度增殖性病症的治疗中用作mps-1和tkk抑制剂的咪唑并吡嗪 | |
| CN103403006B (zh) | 在过度增殖性病症的治疗中用作mps-1和tkk抑制剂的6-硫代-取代的咪唑并吡嗪 | |
| JP2017503809A (ja) | アミド置換イミダゾピリダジン | |
| CN103649087B (zh) | 取代的咪唑并吡啶及其中间体 | |
| HK1173444A (en) | Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors | |
| HK1168791B (en) | Substituted imidazoquinoxalines |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1173444 Country of ref document: HK |
|
| ASS | Succession or assignment of patent right |
Owner name: BAYER INTELLECTUAL PROPERTY GMBH Free format text: FORMER OWNER: BAYER PHARMA AG Effective date: 20130722 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20130722 Address after: German Monheim Applicant after: Bayer Pharma Aktiengesellschaft Address before: Berlin Applicant before: Bayer Pharma AG |
|
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20120718 |
|
| RJ01 | Rejection of invention patent application after publication |